Quest Diagnostics Incorporated (DGX) : During the past 4 weeks, traders have been relatively bearish on Quest Diagnostics Incorporated (DGX), hence the stock is down -2.95% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.43% relative to the S&P 500. The stock has risen by 0.07% in the past week indicating that the buyers are active at lower levels, but the stock is down -3.08% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.8% and the 50-Day Moving Average is 0.56%.The 200 Day SMA reached 12.93%. Quest Diagnostics Inc. is up 7.3% in the last 3-month period. Year-to-Date the stock performance stands at 18.62%.
Quest Diagnostics Incorporated (NYSE:DGX): After opening at $82.67, the stock dipped to an intraday low of $82.295 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $83.22 and the buying power remained strong till the end. The stock closed at $83.04 for the day, a gain of 0.83% for the day session. The total traded volume was 2,303,179. The stocks close on the previous trading day was $82.36.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.